Michael E. Hurwitz

4.6k total citations
76 papers, 1.1k citations indexed

About

Michael E. Hurwitz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Michael E. Hurwitz has authored 76 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 32 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Michael E. Hurwitz's work include Cancer Immunotherapy and Biomarkers (34 papers), Renal cell carcinoma treatment (24 papers) and CAR-T cell therapy research (15 papers). Michael E. Hurwitz is often cited by papers focused on Cancer Immunotherapy and Biomarkers (34 papers), Renal cell carcinoma treatment (24 papers) and CAR-T cell therapy research (15 papers). Michael E. Hurwitz collaborates with scholars based in United States, Australia and Italy. Michael E. Hurwitz's co-authors include Gerd A. Blobel, Harriet M. Kluger, Mario Sznol, Bryden Considine, H. Robert Horvitz, Caterina Strambio‐De‐Castillia, Günter Blobel, Laird Bloom, Adi Diab and Pamela J. Vanderzalm and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

Michael E. Hurwitz

69 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael E. Hurwitz United States 19 582 364 323 290 128 76 1.1k
Haruko Shima Japan 13 190 0.3× 505 1.4× 80 0.2× 207 0.7× 307 2.4× 34 1.2k
Carolina Vicente‐Dueñas Spain 18 495 0.9× 728 2.0× 124 0.4× 147 0.5× 244 1.9× 41 1.2k
Jiayun Lu United States 17 310 0.5× 659 1.8× 260 0.8× 273 0.9× 229 1.8× 53 1.5k
Denis M. Schewe Germany 18 632 1.1× 653 1.8× 115 0.4× 308 1.1× 316 2.5× 54 1.6k
Aude-Hélène Capietto United States 15 468 0.8× 333 0.9× 82 0.3× 615 2.1× 86 0.7× 21 1.1k
Ari J. Rosenberg United States 14 336 0.6× 141 0.4× 160 0.5× 74 0.3× 83 0.6× 69 636
Gregor Werba United States 13 571 1.0× 390 1.1× 147 0.5× 429 1.5× 182 1.4× 27 1.1k
Humberto Contreras-Trujillo United States 7 376 0.6× 461 1.3× 178 0.6× 630 2.2× 72 0.6× 9 1.2k
C. Soon Lee Australia 20 364 0.6× 325 0.9× 153 0.5× 37 0.1× 240 1.9× 39 1.0k
Chencheng Han China 10 556 1.0× 530 1.5× 151 0.5× 276 1.0× 417 3.3× 11 1.1k

Countries citing papers authored by Michael E. Hurwitz

Since Specialization
Citations

This map shows the geographic impact of Michael E. Hurwitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael E. Hurwitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael E. Hurwitz more than expected).

Fields of papers citing papers by Michael E. Hurwitz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael E. Hurwitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael E. Hurwitz. The network helps show where Michael E. Hurwitz may publish in the future.

Co-authorship network of co-authors of Michael E. Hurwitz

This figure shows the co-authorship network connecting the top 25 collaborators of Michael E. Hurwitz. A scholar is included among the top collaborators of Michael E. Hurwitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael E. Hurwitz. Michael E. Hurwitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hurwitz, Michael E., et al.. (2025). Immune checkpoint inhibitor-induced diabetes can potentially be effectively treated with infliximab: a case report of two patients. Frontiers in Endocrinology. 16. 1697724–1697724.
2.
Thomas, Sajeve, Brian S. Henick, Rom S. Leidner, et al.. (2024). Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2542–2542.
3.
Uhlig, Johannes, Annemarie Uhlig, Hari A. Deshpande, et al.. (2024). Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients. Scientific Reports. 14(1). 10038–10038.
4.
Schoenfeld, David A., Dijana Djureinovic, David Su, et al.. (2024). Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti–CTLA-4 in renal cell carcinoma. JCI Insight. 10(1). 6 indexed citations
5.
Rahman, Syed N., Jessica B. Long, Michael Leapman, et al.. (2024). Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open. 7(4). e248747–e248747. 1 indexed citations
6.
Jilaveanu, Lucia B., Adebowale Adeniran, David Su, et al.. (2024). TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3. Cancer Immunology Immunotherapy. 73(10). 192–192. 2 indexed citations
7.
Atkins, Michael B., Opeyemi A. Jegede, Naomi B. Haas, et al.. (2023). Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). Journal for ImmunoTherapy of Cancer. 11(3). e004780–e004780. 19 indexed citations
8.
Chow, Ryan D., Jessica B. Long, Stephanie B. Wheeler, et al.. (2023). Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma. JNCI Cancer Spectrum. 7(3). 5 indexed citations
9.
Kluger, Harriet M., J. Carl Barrett, Justin F. Gainor, et al.. (2023). Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. 11(3). e005921–e005921. 40 indexed citations
10.
Goldberg, Sarah B., et al.. (2023). A multifaceted approach to wellness in a hematology/oncology fellowship program.. Journal of Clinical Oncology. 41(16_suppl). 11006–11006.
11.
Tannir, Nizar M., Adi Diab, Mario Sznol, et al.. (2022). Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. Journal for ImmunoTherapy of Cancer. 10(4). e004419–e004419. 21 indexed citations
12.
Jessel, Shlomit, Sarah A. Weiss, Matthew Austin, et al.. (2022). Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function. Frontiers in Oncology. 12. 836859–836859. 47 indexed citations
13.
Considine, Bryden, Adebowale Adeniran, & Michael E. Hurwitz. (2021). Current Understanding and Management of Intraductal Carcinoma of the Prostate. Current Oncology Reports. 23(9). 110–110. 1 indexed citations
14.
Asad, Mohammad, Brian Shuch, Kevin A. Nguyen, et al.. (2020). Eighteenth International Kidney Cancer Symposium, November 15-16, 2019, Trump National Doral Miami Hotel, Miami, Florida. 4(s1). SI–S56. 1 indexed citations
15.
Hurwitz, Michael E., et al.. (2019). Outcomes of combination therapy with tyrosine kinase inhibitors and immune checkpoint inhibitors in metastatic renal cell carcinoma – A retrospective study. Journal of Oncology Pharmacy Practice. 26(3). 556–563. 3 indexed citations
16.
Bentebibel, Salah-Eddine, Michael E. Hurwitz, Chantale Bernatchez, et al.. (2019). A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. Cancer Discovery. 9(6). 711–721. 169 indexed citations
17.
Zhang, Jialing, Bao‐Hui Cheng, Alexey Bersenev, et al.. (2019). A versatile flow-based assay for immunocyte-mediated cytotoxicity. Journal of Immunological Methods. 474. 112668–112668. 10 indexed citations
18.
Hurwitz, Michael E., et al.. (2015). Supply and Demand in the Higher Education Market: College Enrollment. Research Brief.. 1 indexed citations
19.
Hurwitz, Michael E. & Jessica Howell. (2013). Measuring the Impact of High School Counselors on College Enrollment. Research Brief.. 1 indexed citations
20.
Smith, Jonathan, Matea Pender, Jessica Howell, & Michael E. Hurwitz. (2012). The CollegeKeys Compact™. Getting into College: Postsecondary Academic Undermatch.. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Haruko Shima Breakdown of academic impact, for papers by Carolina Vicente‐Dueñas Breakdown of academic impact, for papers by Jiayun Lu Breakdown of academic impact, for papers by Denis M. Schewe Breakdown of academic impact, for papers by Aude-Hélène Capietto Breakdown of academic impact, for papers by Ari J. Rosenberg Breakdown of academic impact, for papers by Gregor Werba Breakdown of academic impact, for papers by Humberto Contreras-Trujillo Breakdown of academic impact, for papers by C. Soon Lee Breakdown of academic impact, for papers by Chencheng Han
Rankless by CCL
2026